Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 317

1.

Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness.

Milberg P, Frommeyer G, Ghezelbash S, Rajamani S, Osada N, Razvan R, Belardinelli L, Breithardt G, Eckardt L.

Europace. 2013 May;15(5):761-9. doi: 10.1093/europace/eus399. Epub 2013 Feb 1.

PMID:
23376977
2.

Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.

Frommeyer G, Milberg P, Uphaus T, Kaiser D, Kaese S, Breithardt G, Eckardt L.

Cardiovasc Ther. 2013 Dec;31(6):e63-71. doi: 10.1111/1755-5922.12035.

PMID:
23647657
3.

Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure.

Frommeyer G, Schmidt M, Clauß C, Kaese S, Stypmann J, Pott C, Eckardt L, Milberg P.

Eur J Heart Fail. 2012 Dec;14(12):1322-31. doi: 10.1093/eurjhf/hfs163. Epub 2012 Oct 25.

4.

Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.

Kirchhof P, Engelen M, Franz MR, Ribbing M, Wasmer K, Breithardt G, Haverkamp W, Eckardt L.

Basic Res Cardiol. 2005 Mar;100(2):112-21. Epub 2005 Feb 9.

PMID:
15696400
5.

Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.

Kumar K, Nearing BD, Carvas M, Nascimento BC, Acar M, Belardinelli L, Verrier RL.

J Cardiovasc Electrophysiol. 2009 Jul;20(7):796-802. doi: 10.1111/j.1540-8167.2009.01437.x. Epub 2009 Feb 27.

PMID:
19298570
6.

Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.

Milberg P, Tegelkamp R, Osada N, Schimpf R, Wolpert C, Breithardt G, Borggrefe M, Eckardt L.

J Cardiovasc Electrophysiol. 2007 Jun;18(6):658-64.

PMID:
17521304
7.

Electrophysiological profile of vernakalant in an experimental whole-heart model: the absence of proarrhythmia despite significant effect on myocardial repolarization.

Frommeyer G, Milberg P, Clauss C, Schmidt M, Ramtin S, Kaese S, Grundmann F, Grotthoff JS, Pott C, Eckardt L.

Europace. 2014 Aug;16(8):1240-8. doi: 10.1093/europace/euu014. Epub 2014 Apr 2.

PMID:
24696223
8.

Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.

Burashnikov A, Di Diego JM, Barajas-Martínez H, Hu D, Cordeiro JM, Moise NS, Kornreich BG, Belardinelli L, Antzelevitch C.

Circ Heart Fail. 2014 Jul;7(4):627-33. doi: 10.1161/CIRCHEARTFAILURE.114.001129. Epub 2014 May 29. Erratum in: Circ Heart Fail. 2015 Jul;8(4):841. Zygmunt, Andy [removed].

9.

Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits.

Aidonidis I, Doulas K, Hatziefthimiou A, Tagarakis G, Simopoulos V, Rizos I, Tsilimingas N, Molyvdas PA.

J Cardiovasc Pharmacol Ther. 2013 Jan;18(1):94-101. doi: 10.1177/1074248412453874. Epub 2012 Aug 7.

PMID:
22872232
10.

Ranolazine terminates atrial flutter and fibrillation in a canine model.

Bhimani AA, Yasuda T, Sadrpour SA, Khrestian CM, Lee S, Zeng D, Belardinelli L, Waldo AL.

Heart Rhythm. 2014 Sep;11(9):1592-9. doi: 10.1016/j.hrthm.2014.05.038. Epub 2014 Jun 2.

PMID:
25066042
11.

Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.

Burashnikov A, Belardinelli L, Antzelevitch C.

J Pharmacol Exp Ther. 2012 Jan;340(1):161-8. doi: 10.1124/jpet.111.186395. Epub 2011 Oct 17.

12.

Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol.

Burashnikov A, Pourrier M, Gibson JK, Lynch JJ, Antzelevitch C.

Circ Arrhythm Electrophysiol. 2012 Apr;5(2):400-8. doi: 10.1161/CIRCEP.111.968305. Epub 2012 Feb 9.

13.

New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia.

Frommeyer G, Rajamani S, Grundmann F, Stypmann J, Osada N, Breithardt G, Belardinelli L, Eckardt L, Milberg P.

J Card Fail. 2012 Dec;18(12):939-49. doi: 10.1016/j.cardfail.2012.10.017.

PMID:
23207083
14.

Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs.

Duytschaever M, Blaauw Y, Allessie M.

Cardiovasc Res. 2005 Jul 1;67(1):69-76. Epub 2005 Mar 19.

PMID:
15949471
15.

Divergent effect of acute ventricular dilatation on the electrophysiologic characteristics of d,l-sotalol and flecainide in the isolated rabbit heart.

Eckardt L, Haverkamp W, Göttker U, Madeja M, Johna R, Borggrefe M, Breithardt G.

J Cardiovasc Electrophysiol. 1998 Apr;9(4):366-83.

PMID:
9581953
16.

Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent.

Frommeyer G, Sterneberg M, Dechering DG, Kaese S, Bögeholz N, Pott C, Fehr M, Bogossian H, Milberg P, Eckardt L.

Cardiovasc Ther. 2017 Apr;35(2). doi: 10.1111/1755-5922.12244.

PMID:
28039911
17.

Effects of intrapericardial sotalol and flecainide on transmural atrial electrophysiology and atrial fibrillation.

van Brakel TJ, Hermans JJ, Accord RE, Schotten U, Smits JF, Allessie MA, Maessen JG.

J Cardiovasc Electrophysiol. 2009 Feb;20(2):207-15. doi: 10.1111/j.1540-8167.2008.01318.x. Epub 2008 Oct 30.

PMID:
19175851
18.

Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence.

Osaka T, Yamazaki M, Yokoyama E, Ito A, Kodama I.

J Cardiovasc Electrophysiol. 2004 Aug;15(8):877-84.

PMID:
15333078
19.

Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.

Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C.

J Am Coll Cardiol. 2010 Oct 5;56(15):1216-24. doi: 10.1016/j.jacc.2010.08.600.

20.

Reduction of atrial fibrillation by Tanshinone IIA in chronic heart failure.

He Z, Sun C, Xu Y, Cheng D.

Biomed Pharmacother. 2016 Dec;84:1760-1767. doi: 10.1016/j.biopha.2016.10.110. Epub 2016 Nov 12.

PMID:
27847200

Supplemental Content

Support Center